Weather in Kaunas

Time in

Vilnius, Tallinn, Riga

www.worldpharmanews.com

Syndicate content World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements.
Updated: 13 hours 42 min ago

How good cholesterol turns bad

Wed, 02/22/2012 - 00:00
Researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) have found new evidence to explain how cholesteryl ester transfer protein (CETP) mediates the transfer of cholesterol from "good" high density lipoproteins (HDLs) to "bad" low density lipoproteins (LDLs).


Categories: Category 2

BRILINTA® added to American College of Chest Physicians recommendations

Wed, 02/22/2012 - 00:00
AstraZeneca (NYSE: AZN) announced that the American College of Chest Physicians (ACCP) has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to include a recommendation for giving the oral antiplatelet medicine, BRILINTA® (ticagrelor) tablets with low-dose aspirin to patients who suffer from Acute Coronary Syndrome (ACS).


Categories: Category 2

Pfizer and Hisun announce progress on potential joint venture

Tue, 02/21/2012 - 00:00
Pfizer Inc. (NYSE: PFE) and Zhejiang Hisun Pharmaceutical (SSE Code: 600267), a leading pharmaceutical company in China, signed a framework agreement, advancing their previously announced memorandum of understanding (MOU) to establish a joint venture to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.


Categories: Category 2

Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-Eye

Tue, 02/21/2012 - 00:00
Top-line results with VEGF Trap-Eye (aflibercept injection) after one year of treatment in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO) confirm the primary endpoint results that were seen after 24 weeks from the two pivotal trials, GALILEO and COPERNICUS.


Categories: Category 2

Bristol-Myers Squibb Foundation Announces Grants Focused on Prevention, Diagnosis and Care of Hepatitis B and Hepatitis C in Asia

Mon, 02/20/2012 - 00:00
The Bristol-Myers Squibb Foundation has awarded three new grants to improve prevention, diagnosis and care of hepatitis B (HBV) and hepatitis C (HCV) in China and India as part of its Delivering Hope™: Awareness, Prevention and Care umbrella program which is committed to reducing hepatitis-related health disparities in Asia.


Categories: Category 2

EU and US Regulatory Update - Tykerb/Tyverb® (lapatinib)

Fri, 02/17/2012 - 00:00
GlaxoSmithKline has submitted regulatory applications in Europe and the US related to Tykerb/ Tyverb (lapatinib) and its use in combination with trastuzumab to treat patients with HER2 (ErbB2)-positive metastatic breast cancer.


Categories: Category 2

Positive top-line result for UCB's Cimzia® in psoriatic arthritis

Fri, 02/17/2012 - 00:00
UCB intends to submit regulatory applications for Cimzia® (certolizumab pegol) in psoriatic arthritis, by end of 2012. Top-line results from the RAPID-PsA™ phase 3 study evaluating the efficacy and safety of Cimzia® in patients with adult onset active psoriatic arthritis (PsA) demonstrated a clinically relevant and statistically significant improvement.


Categories: Category 2

Video games lead to new paths to treat cancer

Thu, 02/16/2012 - 10:00
In a research lab at Wake Forest University, biophysicist and computer scientist Samuel Cho uses graphics processing units (GPUs), the technology that makes videogame images so realistic, to simulate the inner workings of human cells.


Categories: Category 2

Merck Establishes Joint Venture with Supera Farma

Thu, 02/16/2012 - 00:00
Merck (NYSE:MRK), known as MSD outside the United States and Canada, has announced the formation of a new joint venture (JV) with Supera Farma Laboratorios S.A., a Brazilian pharmaceutical company co-owned by Cristália and Eurofarma.


Categories: Category 2

Cell discovery strengthens quest for cancer treatments

Wed, 02/15/2012 - 00:00
Fresh insights into how our cells multiply could help scientists develop drugs to treat cancer. Researchers have gained better understanding of the workings of two key proteins that control cell division. This process must be carried out accurately to keep cells healthy, and when it goes out of control, it can lead to cancer.


Categories: Category 2

Lilly releases its most comprehensive corporate responsibility report

Wed, 02/15/2012 - 00:00
Eli Lilly and Company (NYSE: LLY) has released its most comprehensive corporate responsibility report using the Global Reporting Initiative (GRI) framework, which is designed to help companies report on economic, environmental and social performance.


Categories: Category 2

Bristol-Myers Squibb Completes Acquisition of Inhibitex, Inc.

Tue, 02/14/2012 - 00:00
Bristol-Myers Squibb Company (NYSE: BMY) announced today the successful completion of the tender offer by Bristol-Myers Squibb Company ("Bristol-Myers") for all of the outstanding shares of common stock of Inhibitex, Inc. (NASDAQ: INHX) ("Inhibitex") at a purchase price of $26.00 per share.


Categories: Category 2

FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer

Tue, 02/14/2012 - 00:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.


Categories: Category 2

New findings show how some cells protect themselves against HIV

Mon, 02/13/2012 - 00:00
A protein that protects some of our immune cells from the most common and virulent form of HIV works by starving the virus of the molecular building blocks that it needs to replicate, according to research published online in Nature Immunology.


Categories: Category 2

Fifth Lilly Oncology on Canvas Art Competition invites all touched by cancer

Fri, 02/10/2012 - 00:00
Get your canvases, paintbrushes and cameras ready - the subject is cancer and you are the storyteller. Lilly Oncology and the National Coalition for Cancer Survivorship (NCCS) announced the launch of the 2012 Lilly Oncology On Canvas: Expressions of a Cancer Journey Art Competition and Exhibition.


Categories: Category 2

Sanofi fourth-quarter and full-year net sales

Thu, 02/09/2012 - 00:00
In the fourth quarter of 2011, Sanofi generated sales of €8,508 million, up 8.8% on a reported basis. Exchange rate movements had a negative effect of 0.4 percentage points.


Categories: Category 2

Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex

Thu, 02/09/2012 - 00:00
Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix® (clopidogrel bisulfate) patent infringement case against Apotex.


Categories: Category 2

Roche in 2011: Strong results and positive outlook

Wed, 02/08/2012 - 00:00
The Roche Group posted strong operating results in a challenging market in 2011. Core operating profit grew faster than sales, and Core Earnings per Share increased by 11% at constant exchange rates (-4% in Swiss francs).


Categories: Category 2

New technology to tackle treatment-resistant cancers

Tue, 02/07/2012 - 00:00
Free-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies.


Categories: Category 2

Warfarin and aspirin are similar in heart failure treatment

Mon, 02/06/2012 - 00:00
In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.


Categories: Category 2
  • Professionalism.
    We are specialists in this field and like our activity, so we can guarantee the quality of our work.
  • Competitiveness.
    Individual solutions for a competitive price.
  • Confidentiality.
    We appreciate the cooperation, maintain confidentiality and seek for a long-term partnership
 

My status

Member of Medicines Manufacturers Association